Allegan plc announced today it has received clearance from the U.S. FDA for use of the XEN® Glaucoma Treatment System in the United States.
The XEN Glaucoma Treatment System was reportedly designed to reduce intraocular pressure (IOP) in patients, and is indicated for the management of refractory glaucomas, where previous surgical treatment has failed or in patients with primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.
The system consists of the XEN45 Gel Stent and the XEN Injector. XEN is reportedly implanted through an ab interno approach and reduces IOP by creating a new drainage channel with a permanent implant that becomes flexible. Allergan reportedly plans to launch the XEN Glaucoma Treatment System in the U.S. in early 2017.
Click here to read the full press release.